Calcium, magnesium, potassium and sodium oxybates (Xywav)
Small molecule
Evidence outlook
Approved: Idiopathic Hypersomnia, Narcolepsy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
55 registry matches · 57 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other GABA-B receptor drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Narcolepsy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav): this drug | Approved | Small molecule | GABA-B receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Modafinil (Provigil) | Approved | Small molecule | Sympathomimetic-like Agent | not yet graded | No reviewed efficacy summary in this indication | |
| Oveporexton (Orzeyful) | Approved | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant (Wakix) | Approved | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | Reliable signal | NCT02611687: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35) | |
| Sodium Oxybate | Approved | Small molecule | GABA-B receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Solriamfetol (Sunosi) | Approved | Small molecule | Dopamine/norepinephrine transporter | Partial signal | NCT02348632: Change in Epworth Sleepiness Scale score from the start to the end of the 2-week randomized-withdrawal period (positive = worse): +1.6 with continued solriamfetol (n=139) vs +5.3 after switch to placebo (n=141); difference -3.7 points (95% CI -4.8 to -2.7), significant after multiplicity adjustment (SUNOSI label Table 8; CT.gov posted results). NCT02348593: Change from baseline to week 12 vs placebo: MWT +12.3 (300 mg) and +9.8 (150 mg) vs +2.1 minutes; ESS -6.4 and -5.4 vs -1.6 points (all p<0.0001). The 75 mg dose (MWT +4.74, ESS -3.8) was not statistically significant on either coprimary (Thorpy et al., Ann Neurol 2019; SUNOSI label). | |
| Alixorexton | Phase 3 | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Reboxetine | Phase 3 | Small molecule | norepinephrine transporter | Partial signal | NCT05113745: Primary endpoint, change in frequency of cataplexy attacks in the randomized withdrawal phase: statistically significant improvement vs placebo (Axsome, 2024-11-26). | |
| Cleminorexton | Phase 2/3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-360 | Phase 2/3 | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant GR | —(overall) | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Calcium, magnesium, potassium and sodium oxybates (Xywav) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
January 2027 (1)
What to watch
September 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (1)
December 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent